Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0049-3848(79)90021-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Medical Adjuvant Therapy in Reducing Thrombosis With Arteriovenous Grafts and Fistulae Use: A Meta-Analysis of Randomized Controlled Trials.
Clin Appl Thromb Hemost
March 2022
27890Universidad Espíritu Santo, Samborondón, Ecuador.
Hemodialysis is required for patients with end-stage renal disease (ESRD) that require arteriovenous (AV) grafts or fistulas for vascular access. These access points are prone to thrombosis. To determine the effect of medical adjuvant therapy on AV graft/fistula patency among patients with ESRD on hemodialysis.
View Article and Find Full Text PDFMedical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
Cochrane Database Syst Rev
July 2021
Department of Vascular Surgery, Wrexham Maelor Hospital, Wrexham, UK.
Background: People with end-stage renal disease (ESRD) often require either the formation of an arteriovenous fistula (AVF) or an interposition prosthetic arteriovenous graft (AVG) for haemodialysis. These access sites should ideally have a long life and a low rate of complications (e.g.
View Article and Find Full Text PDFThe impact of adoption of a new urate-lowering agent on trends in utilization and cost in practice.
PLoS One
March 2020
School of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan.
Objectives: Changes in treatment choice of therapy and size of treated population that can lead to under- or overestimate of payer's budget are less likely to be reassured after reimbursement adoption of a new drug. The aim of this study was to evaluate the effects of febuxostat introduction and the modifications in its insurance coverage on the utilization and expenditure of urate-lowering therapy (ULT).
Methods: Electronic medical records for adults patients prescribed any ULT during 2010-2015 was derived from the largest medical organization in Taiwan.
Medical Adjuvant Treatment to Improve the Patency of Arteriovenous Fistulae and Grafts: A Systematic Review and Meta-analysis.
Eur J Vasc Endovasc Surg
August 2016
Department of Vascular Surgery, Wrexham Maelor Hospital, Wrexham LL13 7TD, UK.
Background: Many patients using haemodialysis for end-stage renal disease (ESRD) require arteriovenous fistulae (AVF) or grafts. Patency can be variable, and this systematic review aimed to determine the effects of adjuvant drug treatment on the patency of AVFs and grafts.
Methods: The Cochrane Peripheral Vascular Diseases Group searched the Specialised Register and CENTRAL for all randomised controlled trials (RCTs) investigating the effect of active drug versus placebo on patency.
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
Cochrane Database Syst Rev
July 2015
Department of Vascular Surgery, Wrexham Maelor Hospital, Croesnewydd Road, Wrexham, UK, LL13 7TD.
Background: End-stage renal disease (ESRD) patients often require either the formation of an arteriovenous (AV) fistula or an AV interposition prosthetic shunt for haemodialysis. These access sites should ideally have a long life and a low rate of complications (for example thrombosis, infection, stenosis, aneurysm formation and distal limb ischaemia). Although some of the complications may be unavoidable, any adjuvant technique or medical treatment aimed at decreasing complications would be welcome.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!